PTC Therapeutics Presents 2026 Total Revenue Guidance of $1.29 Billion-$1.32 Billion
Bitget2026/10/29 21:02- PTC Therapeutics projects 2026 total revenue of $1.29 billion–$1.32 billion, with operating expenses of $680 million–$720 million.
- Product revenue guidance of $960 million–$990 million represents 64%–69% year-over-year growth.
- Sephience generated $458 million in year-to-date global revenue during its first full launch year.
- Cash totaled $2.1 billion, with cash flow breakeven targeted for the year.
- The ST-920 gene therapy application for accelerated approval in Fabry disease is expected to be completed in the fourth quarter.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
